COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

Abstract

A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.

• Authors: Piercarlo Sarzi-Puttini, Valeria Giorgi, Silvia Sirotti, Daniela Marotto, Sandro Ardizzone, Giuliano Rizzardini, Spinello Antinori, Massimo Galli
• Journal: Clinical and experimental rheumatology (Clin Exp Rheumatol) 2020 Mar-Apr Vol. 38 Issue 2 Pg. 337-342 ISSN: 0392-856X [Print] Italy
• PMID: 32202240 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents
• Antirheumatic Agents
• Cytokines

Topics

• Anti-Inflammatory Agents (therapeutic use)
• Antirheumatic Agents (therapeutic use)
• Betacoronavirus
• COVID-19
• China (epidemiology)
• Coronavirus Infections (drug therapy, epidemiology, immunology)
• Cytokines (metabolism)
• Humans
• Infection Control
• Pandemics
• Pneumonia, Viral (drug therapy, epidemiology, immunology)
• SARS-CoV-2
• Severe Acute Respiratory Syndrome (drug therapy, epidemiology, immunology)
• COVID-19 Drug Treatment